Scarica l'app Stockscreener
25.62
1.50%
-0.39
Dopo l'orario di chiusura:
25.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$26.01
Aprire:
$26.455
Volume 24 ore:
583.36K
Relative Volume:
0.70
Capitalizzazione di mercato:
$1.65B
Reddito:
$32.08M
Utile/perdita netta:
$-169.77M
Rapporto P/E:
-9.0154
EPS:
-2.8418
Flusso di cassa netto:
$-147.70M
1 W Prestazione:
+3.31%
1M Prestazione:
-16.00%
6M Prestazione:
-21.75%
1 anno Prestazione:
+3.22%
Intervallo 1D:
$25.45
$26.45
Intervallo di 1 settimana:
$24.20
$26.69
Portata 52W:
$20.32
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
25.62 | 1.60B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board - AD HOC NEWS
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - Kalkine Media
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue - AD HOC NEWS
Ruth Walker Appointed Vice President, People & Culture at Stoke Therapeutics - hrtoday.in
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com India
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, E - The National Law Review
Stoke Therapeutics appoints Bo Cumbo to board of directors By Investing.com - Investing.com Canada
STOK Looks 163.2% Overvalued on GF Value™ - GuruFocus
Stoke Therapeutics appoints Bo Cumbo to board of directors - Investing.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9%What's Next? - MarketBeat
Stoke Therapeutics Appoints Bo Cumbo to Its B - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
News - planetario.buenosaires.gob.ar
Stoke Therapeutics stock holds gains after recent data update - AD HOC NEWS
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology - DirectorsTalk Interviews
ETFs Investing in Stoke Therapeutics, Inc. Stocks - TradingView
Stoke (STOK) Breaks Out with +4.23% Surge Past $30.54 2026-09-17Zero Lag EMA - siam.in
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 - BioSpace
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics at Cantor conference: dravet data, cash runway - Investing.com
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - The Manila Times
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Stoke Therapeutics Inc Azioni (STOK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 14 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
30,422 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 18 '26 |
Sale |
32.03 |
4,767 |
152,690 |
25,655 |
| Kaye Edward M. MD | Director |
Aug 14 '26 |
Option Exercise |
0.00 |
26,250 |
0 |
137,124 |
| Kaye Edward M. MD | Director |
Aug 18 '26 |
Sale |
32.03 |
12,567 |
402,528 |
124,557 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 14 '26 |
Option Exercise |
0.00 |
6,000 |
0 |
24,086 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 18 '26 |
Sale |
32.03 |
2,861 |
91,639 |
21,225 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 03 '26 |
Sale |
29.04 |
7,176 |
208,385 |
20,422 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):